{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:21:14Z","timestamp":1791343274516,"version":"4.3.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Actinic keratosis (AK) are precancerous lesions of the skin which may progress to invasive squamous cell carcinoma. However, single lesions may also persist or even regress and heal spontaneously. Until now, evidence on the natural course of AK including spontaneous regression is limited. We aimed to synthesize regression rates of AK. We performed a systematic literature research in Medline, Embase, and CENTRAL for eligible trials until 3rd March 2020. Spontaneous regression rates were pooled using a random-effects model to calculate pooled proportions of participant-specific and lesion-specific complete clearance rates reported for the placebo arms of randomized controlled trials. Subgroup analyses were performed to dissect differences according to the type of placebo, immunocompetence of the participants, and localization of the lesions. Data from 38 records was included. The pooled participant-specific clearance rate was 8% (95% CI 6\u201310%, I<jats:sup>2<\/jats:sup>\u2009=\u200971%) while the lesion-specific clearance rate was 23% (95% CI 16\u201331%, I<jats:sup>2<\/jats:sup>\u2009=\u200997%). The highest participant- and lesion-specific clearance rates were achieved 12\u00a0weeks after the end of treatment (12%\u00a0and\u00a033%, respectively). Subgroup analysis revealed participant- as well as lesion-specific clearance rates of 0% for organ transplant recipients (OTR). We conclude that\u00a0only a few participants achieve complete regression of their AK without any active treatment. Besides, the results underline that lesion clearance\u00a0without active treatment is unlikely in OTR. Thus, early and consequent treatment of AK is recommended. Special attention should be paid when treating AK of OTR.<\/jats:p>","DOI":"10.1038\/s41598-022-09722-8","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T17:03:26Z","timestamp":1649351006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Spontaneous regression rates of actinic keratosis: a systematic review and pooled analysis of randomized controlled trials"],"prefix":"10.1038","volume":"12","author":[{"given":"Theresa","family":"Steeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annkathrin","family":"Hornung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Wessely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"1 Pt 2","key":"9722_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1067\/mjd.2000.103342","volume":"42","author":"SJ Salasche","year":"2000","unstructured":"Salasche, S. J. Epidemiology of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42(1 Pt 2), 4\u20137 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1 Pt 2","key":"9722_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1067\/mjd.2000.103343","volume":"42","author":"RL Moy","year":"2000","unstructured":"Moy, R. L. Clinical presentation of actinic keratoses and squamous cell carcinoma. J. Am. Acad. Dermatol. 42(1 Pt 2), 8\u201310 (2000).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"Suppl 3","key":"9722_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.07860.x","volume":"156","author":"J R\u00f6wert-Huber","year":"2007","unstructured":"R\u00f6wert-Huber, J. et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br. J. Dermatol. 156(Suppl 3), 8\u201312 (2007).","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"9722_CR4","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1111\/jgs.16706","volume":"68","author":"SP Sinikumpu","year":"2020","unstructured":"Sinikumpu, S. P. et al. The high prevalence of skin diseases in adults aged 70 and older. J. Am. Geriatr. Soc. 68(11), 2565\u20132571 (2020).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"3","key":"9722_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/jdv.12102","volume":"28","author":"I Schaefer","year":"2014","unstructured":"Schaefer, I. et al. Prevalence and risk factors of actinic keratoses in Germany\u2013analysis of multisource data. J. Eur. Acad. Dermatol. Venereol. 28(3), 309\u2013313 (2014).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"11","key":"9722_CR6","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1001\/jamadermatol.2018.3086","volume":"154","author":"H Yeung","year":"2018","unstructured":"Yeung, H. et al. Use and cost of actinic keratosis destruction in the medicare part B fee-for-service population, 2007 to 2015. JAMA Dermatol. 154(11), 1281\u20131285 (2018).","journal-title":"JAMA Dermatol."},{"issue":"4","key":"9722_CR7","first-page":"20","volume":"5","author":"MS Nestor","year":"2012","unstructured":"Nestor, M. S. & Zarraga, M. B. The incidence of nonmelanoma skin cancers and actinic keratoses in South Florida. J. Clin. Aesthet. Dermatol. 5(4), 20\u201324 (2012).","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"11","key":"9722_CR8","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1002\/cncr.24284","volume":"115","author":"VD Criscione","year":"2009","unstructured":"Criscione, V. D. et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 115(11), 2523\u20132530 (2009).","journal-title":"Cancer"},{"issue":"3","key":"9722_CR9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/bjd.12420","volume":"169","author":"RN Werner","year":"2013","unstructured":"Werner, R. N. et al. The natural history of actinic keratosis: a systematic review. Br. J. Dermatol. 169(3), 502\u2013518 (2013).","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"9722_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2340\/00015555-2692","volume":"97","author":"R Cerio","year":"2017","unstructured":"Cerio, R. et al. Actinic keratosis, a chronic, progressive disease: Understanding clinical gaps to optimise patient management. Acta Derm. Venereol. 97(8), 997\u2013998 (2017).","journal-title":"Acta Derm. Venereol."},{"issue":"11","key":"9722_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/jdv.13180","volume":"29","author":"RN Werner","year":"2015","unstructured":"Werner, R. N. et al. Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis\u2014International League of Dermatological Societies in cooperation with the European Dermatology Forum\u2014Short version. J. Eur. Acad. Dermatol. Venereol. 29(11), 2069\u20132079 (2015).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"9722_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.15107","volume":"176","author":"D de Berker","year":"2017","unstructured":"de Berker, D. et al. British Association of Dermatologists\u2019 guidelines for the care of patients with actinic keratosis 2017. Br. J. Dermatol. 176(1), 20\u201343 (2017).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"9722_CR13","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","volume":"85","author":"DB Eisen","year":"2021","unstructured":"Eisen, D. B. et al. Guidelines of care for the management of actinic keratosis. J. Am. Acad. Dermatol. 85(4), e209\u2013e233 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"9722_CR14","first-page":"275","volume":"18","author":"MV Heppt","year":"2020","unstructured":"Heppt, M. V. et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: Diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J. Dtsch. Dermatol. Ges. 18(3), 275\u2013294 (2020).","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"2","key":"9722_CR15","first-page":"165","volume":"10","author":"CW Hanke","year":"2011","unstructured":"Hanke, C. W. et al. Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. J. Drugs Dermatol. 10(2), 165\u2013170 (2011).","journal-title":"J. Drugs Dermatol."},{"issue":"1","key":"9722_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1365-2133.2004.06054.x","volume":"151","author":"G Dragieva","year":"2004","unstructured":"Dragieva, G. et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br. J. Dermatol. 151(1), 196\u2013200 (2004).","journal-title":"Br. J. Dermatol."},{"issue":"Suppl 2","key":"9722_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1365-2133.2007.08269.x","volume":"157","author":"C Ulrich","year":"2007","unstructured":"Ulrich, C. et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br. J. Dermatol. 157(Suppl 2), 25\u201331 (2007).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"9722_CR18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1684\/ejd.2010.1010","volume":"20","author":"C Ulrich","year":"2010","unstructured":"Ulrich, C. et al. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur. J. Dermatol. 20(4), 482\u2013488 (2010).","journal-title":"Eur. J. Dermatol."},{"issue":"4","key":"9722_CR19","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/bjd.12158","volume":"168","author":"T Dirschka","year":"2013","unstructured":"Dirschka, T. et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br. J. Dermatol. 168(4), 825\u2013836 (2013).","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"9722_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","volume":"44","author":"K Gebauer","year":"2003","unstructured":"Gebauer, K., Brown, P. & Varigos, G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol. 44(1), 40\u201343 (2003).","journal-title":"Australas. J. Dermatol."},{"issue":"1","key":"9722_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archderm.140.1.41","volume":"140","author":"DJ Piacquadio","year":"2004","unstructured":"Piacquadio, D. J. et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: Investigator-blinded, phase 3, multicenter trials. Arch. Dermatol. 140(1), 41\u201346 (2004).","journal-title":"Arch. Dermatol."},{"issue":"7","key":"9722_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/DSS.0000000000001760","volume":"45","author":"SI Brian Jiang","year":"2019","unstructured":"Brian Jiang, S. I. et al. A randomized, vehicle-controlled phase 3 study of aminolevulinic acid photodynamic therapy for the treatment of actinic keratoses on the upper extremities. Dermatol. Surg. 45(7), 890\u2013897 (2019).","journal-title":"Dermatol. Surg."},{"issue":"5","key":"9722_CR23","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/j.1365-2133.2009.09040.x","volume":"160","author":"A Hauschild","year":"2009","unstructured":"Hauschild, A. et al. Optimization of photodynamic therapy with a novel self-adhesive 5-aminolaevulinic acid patch: Results of two randomized controlled phase III studies. Br. J. Dermatol. 160(5), 1066\u20131074 (2009).","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"9722_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bjd.14498","volume":"175","author":"U Reinhold","year":"2016","unstructured":"Reinhold, U. et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(\u00ae) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(\u00ae) lamp. Br. J. Dermatol. 175(4), 696\u2013705 (2016).","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"9722_CR25","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/jcm9051438","volume":"9","author":"T Steeb","year":"2020","unstructured":"Steeb, T. et al. Treatment motivations and expectations in patients with actinic keratosis: A German-wide multicenter, cross-sectional trial. J. Clin. Med. 9(5), 1438 (2020).","journal-title":"J. Clin. Med."},{"issue":"2","key":"9722_CR26","doi-asserted-by":"publisher","first-page":"e14833","DOI":"10.1111\/dth.14833","volume":"34","author":"A Grada","year":"2021","unstructured":"Grada, A. et al. Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatol. Ther. 34(2), e14833 (2021).","journal-title":"Dermatol. Ther."},{"issue":"Suppl 3","key":"9722_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","volume":"161","author":"C Ulrich","year":"2009","unstructured":"Ulrich, C. et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: A 24 months, prospective, case-control study. Br. J. Dermatol. 161(Suppl 3), 78\u201384 (2009).","journal-title":"Br. J. Dermatol."},{"issue":"16","key":"9722_CR28","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJM199310143291602","volume":"329","author":"SC Thompson","year":"1993","unstructured":"Thompson, S. C., Jolley, D. & Marks, R. Reduction of solar keratoses by regular sunscreen use. N. Engl. J. Med. 329(16), 1147\u20131151 (1993).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"9722_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/archderm.1995.01690140054008","volume":"131","author":"MF Naylor","year":"1995","unstructured":"Naylor, M. F. et al. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch. Dermatol. 131(2), 170\u2013175 (1995).","journal-title":"Arch. Dermatol."},{"issue":"9180","key":"9722_CR30","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(98)12168-2","volume":"354","author":"A Green","year":"1999","unstructured":"Green, A. et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet 354(9180), 723\u2013729 (1999).","journal-title":"Lancet"},{"issue":"5","key":"9722_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/jdv.15459","volume":"33","author":"MV Heppt","year":"2019","unstructured":"Heppt, M. V. et al. Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a meta-analysis. J. Eur. Acad. Dermatol. Venereol. 33(5), 863\u2013873 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"9722_CR32","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.17435","volume":"180","author":"MV Heppt","year":"2019","unstructured":"Heppt, M. V. et al. Cryosurgery combined with topical interventions for actinic keratosis: A systematic review and meta-analysis. Br. J. Dermatol. 180(4), 740\u2013748 (2019).","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"9722_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaad.2019.09.037","volume":"82","author":"T Steeb","year":"2020","unstructured":"Steeb, T. et al. Microneedling-assisted photodynamic therapy for the treatment of actinic keratosis: Results from a systematic review and meta-analysis. J. Am. Acad. Dermatol. 82(2), 515\u2013519 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"9722_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jaad.2018.09.021","volume":"80","author":"T Steeb","year":"2019","unstructured":"Steeb, T. et al. Laser-assisted photodynamic therapy for actinic keratosis: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 80(4), 947\u2013956 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"9722_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/jdv.15998","volume":"34","author":"T Steeb","year":"2020","unstructured":"Steeb, T. et al. The more the better? An appraisal of combination therapies for actinic keratosis. J. Eur. Acad. Dermatol. Venereol. 34(4), 727\u2013732 (2020).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"9722_CR36","first-page":"Cd004415","volume":"12","author":"AK Gupta","year":"2012","unstructured":"Gupta, A. K. et al. Interventions for actinic keratoses. Cochrane Database Syst. Rev. 12, Cd004415 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"9722_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjd.17148","volume":"180","author":"MV Heppt","year":"2019","unstructured":"Heppt, M. V. et al. Local interventions for actinic keratosis in organ transplant recipients: a systematic review. Br. J. Dermatol. 180(1), 43\u201350 (2019).","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"9722_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2340\/00015555-2783","volume":"98","author":"Z Jiyad","year":"2018","unstructured":"Jiyad, Z. et al. Incidence and regression of actinic keratoses in organ transplant recipients. Acta Derm. Venereol. 98(1), 77\u201381 (2018).","journal-title":"Acta Derm. Venereol."},{"issue":"8","key":"9722_CR39","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1200\/JCO.1995.13.8.1933","volume":"13","author":"JN Bavinck","year":"1995","unstructured":"Bavinck, J. N. et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: A double-blind, placebo-controlled study. J. Clin. Oncol. 13(8), 1933\u20131938 (1995).","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"9722_CR40","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1506197","volume":"373","author":"AC Chen","year":"2015","unstructured":"Chen, A. C. et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N. Engl. J. Med. 373(17), 1618\u20131626 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"9722_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1684\/ejd.2017.3025","volume":"27","author":"F Drago","year":"2017","unstructured":"Drago, F. et al. Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: A case-control study. Eur. J. Dermatol. 27(4), 382\u2013385 (2017).","journal-title":"Eur. J. Dermatol."},{"issue":"4","key":"9722_CR42","first-page":"562","volume":"32","author":"CC Otley","year":"2006","unstructured":"Otley, C. C. et al. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: Practical dosing and management of adverse effects. Dermatol. Surg. 32(4), 562\u2013568 (2006).","journal-title":"Dermatol. Surg."},{"issue":"Suppl 2","key":"9722_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1365-2133.2012.11091.x","volume":"167","author":"K Choudhury","year":"2012","unstructured":"Choudhury, K. et al. Effectiveness of skin cancer screening programmes. Br. J. Dermatol. 167(Suppl 2), 94\u201398 (2012).","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"9722_CR44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.euroneuro.2012.04.003","volume":"22","author":"E Czerniak","year":"2012","unstructured":"Czerniak, E. & Davidson, M. Placebo, a historical perspective. Eur. Neuropsychopharmacol. 22(11), 770\u2013774 (2012).","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"9722_CR45","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1046\/j.1528-1157.2001.41601.x","volume":"42","author":"YG Papakostas","year":"2001","unstructured":"Papakostas, Y. G. & Daras, M. D. Placebos, placebo effect, and the response to the healing situation: The evolution of a concept. Epilepsia 42(12), 1614\u20131625 (2001).","journal-title":"Epilepsia"},{"issue":"5","key":"9722_CR46","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000080213","volume":"17","author":"G Weindl","year":"2004","unstructured":"Weindl, G. et al. Hyaluronic acid in the treatment and prevention of skin diseases: Molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol. Physiol. 17(5), 207\u2013213 (2004).","journal-title":"Skin Pharmacol. Physiol."},{"issue":"12","key":"9722_CR47","doi-asserted-by":"publisher","first-page":"782","DOI":"10.12968\/jowc.2020.29.12.782","volume":"29","author":"IC King","year":"2020","unstructured":"King, I. C. & Sorooshian, P. Hyaluronan in skin wound healing: therapeutic applications. J. Wound Care 29(12), 782\u2013787 (2020).","journal-title":"J. Wound Care"},{"issue":"3","key":"9722_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1039\/B910552M","volume":"6","author":"J Gaffney","year":"2010","unstructured":"Gaffney, J. et al. Therapeutic applications of hyaluronan. Mol. Biosyst. 6(3), 437\u2013443 (2010).","journal-title":"Mol. Biosyst."},{"key":"9722_CR49","doi-asserted-by":"crossref","unstructured":"Steeb, T., et al. Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. J. Am. Acad. Dermatol. (2021).","DOI":"10.1038\/s41598-022-09722-8"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09722-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09722-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:33:16Z","timestamp":1669339996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09722-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9722"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09722-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5884"}}